Abstract

Abstract The high binding specificity that monoclonal antibodies exhibit has led to great interest in using them to target tumor-associated antigens. The antibody may be coupled to a radionuclide or cytotoxic drug to create a tumor-targeted reagent that can be used to identify sites of metastatic disease and/or deliver a lethal substance to the tumor cells. However, successful application of these compounds in a clinical setting has been hindered by a poor understanding of the factors that govern antibody accumulation in a tumor. We have used a finite element method to develop a pharmacokinetic model describing the uptake of systemically-administered antibody in an early, prevascular spherical tumor nodule embedded in normal tissue. The model incorporates such processes as plasma kinetics, transcapillary transport, interstitial diffusion, binding reactions, lymphatic clearance, and antigen internalization.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.